@article {1080, title = {Pharmacognostic, Phytochemical and Ethnopharmacological Potential of Cyclamen coum Mill}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {February 2020}, pages = {204-212}, type = {Review Article}, chapter = {204}, abstract = {

Background: This review focuses on characterization of Cyclamen coum Mill. (Myrsinaceae), composition and content of biologically active substances presented in the above-ground and underground parts, reporting use of this plant in traditional medicine, predicting possible pharmacotherapeutic effects. Materials and Methods: Various electronic search engines such as Google, Google scholar, scientific literature, electronic databases such as e-Library, Scopus, Web of Science, Pubmed had been searched and data obtained. Results: Cyclamen L. is classified in the Myrsinaceae family now. It is a typical element of the Mediterranean flora. C. coum. is a species characteristic of the Caucasus and Crimea with rounded leaves and rounded corolla lobes, bright and pink-purple flowers. Chemical composition of biologically active substances of C. coum was described in sufficient detail. C. coum contains saponins (coumoside A, coumoside B, cyclaminorin, deglucocyclamin, cyclacoumin, and mirabilin lactone), sterols (stigmasterol and other related compounds), piperidine alkaloid (2-β-D-glycopyranosyl-2-undecil-3,5-dihydroxy-6-carboxypiperidine), flavonoids, phenols, tannins, cardiac glycosides. Antioxidant, antibacterial, antifungal, and antitumor activities are established for different C. coum extracts. Conclusion: C. coum can be used for the production of potential anticancer, antibacterial and antifungal drugs. It should be noted that more pharmacognostic, pharmacological studies are needed for providing further information to use this medicinal plant in the official medicine. Also, standardization procedures for a crude herbal drug should be developed.

}, keywords = {Coumoside A, Coumoside B, Cyclacumin, Cyclamen coum, Cyclaminorin, Deglucocyclamine}, doi = {10.5530/pj.2020.12.31}, author = {Bokov DO and Krasikova MK and Sergunova EV and Bobkova NV and Kovaleva TYu and Bondar AA and Marakhova AI and Morokhina SL and Krasnyuk II and Moiseev DV} } @article {1125, title = {Pharmacopoeial Analysis of Inulin-Containing Medicinal Plant Raw Materials and Drugs}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {March 2020}, pages = {415-421}, type = {Review Article }, chapter = {415}, abstract = {

Background: Today, there are some unresolved issues and discussions concerning inulin quantitative determination in medicinal plant raw materials (MPRM). MPRM containing polyfructans or fructosans (inulin and others) are rather complex multicomponent matrixes with many interacting compounds. The article discusses the prospects for further standardization of inulin-containing pharmacopoeial MPRM that include, in addition to polysaccharides (inulin), other biologically active compounds with pharmacological activity. Materials and Methods: Different types of search tools such as Google scholar, Google, scientific literature, normative documentation of Russian Federation (State Pharmacopoeia of Russian Federation IV edition and others) electronic databases such as e-Library, Scopus, Web of Science, Pubmed had been searched and data obtained. Results: The pharmacopoeial spectrophotometric procedures of inulin determination in the Russian Federation are approved in a version that does not fully satisfy modern standardization criteria. Regulatory changes required in the near future. Conclusion: Undoubtedly, to determine inulin quantitatively, it is necessary to modify the existing spectrophotometric procedures and introduce an additional alternative, more specific HPLC-RID (or similar) ones.

}, keywords = {Fructosans, HPLC-RID, Inulin quantitative determination, Polyfructans}, doi = {10.5530/pj.2020.12.64}, author = {Bokov DO and Karabeshkin DI and Samylina IA and Potanina OG and Krasnyuk II and Malinkin AD and Sergunova EV and Kovaleva TYu and Bobkova NV and Antsyshkina AM and Bondar AA and Evgrafov AA and Galiakhmetova EK and Moiseev DV and Bessonov VV} } @article {990, title = {Flavonoids in Passiflora incarnata L. Dry Extract of Russian Origin}, journal = {Pharmacognosy Journal}, volume = {11}, year = {2019}, month = {September 2019}, pages = {1143-1147}, type = {Research Article}, chapter = {1143}, abstract = {

Background: Flavonoids are one of the main classes of biologically active substances providing the pharmacotherapeutic effect of passionflower (Passiflora incarnata L.) preparations. In this article studies on the standardization of Passiflora incarnata L. dry extract (PDE) by flavonoids are presented. The aim of this work was to study the composition and content of flavonoids in PDE with the help of precise modern physicochemical methods. Materials and Methods: PDE was prepared from crude herbal drug {\textendash} P. incarnata herb of Russian origin. Reverse phase HPLC-UV analysis was performed with Agilent 1100 liquid chromatograph. Chromatographic column was Atlantis C18 (250 mm {\texttimes} 4.6 mm {\texttimes} 5 μm); analytical wavelength {\textendash} 350 nm; mobile phase {\textendash} 0.01\% formic acid solution and methanol: acetonitrile (25:75); column temperature {\textendash} 35{\textdegree}C; analysis time {\textendash} 90 min; flow rate of the mobile phase {\textendash} 0.8 ml/min in gradient elution mode. Commercially available samples of flavonoids were used for identification and quantitative determination. Results: 20 compounds of flavonoid structure are presented in the PDE. 9 flavonoid compounds have been identified, they are: isovitexin, vitexin, rutoside, hyperoside, luteolin, kaempferol, kaempferitrin, orientin, and isoorientin. The content of vitexin is 0,867 {\textpm} 0,011\%, the total flavonoids content in terms of vitexin is 3,762 {\textpm} 0,049\%. Conclusion: The obtained data will be used to create regulatory documentation for drugs based on PDE.

}, keywords = {Dry extract, Flavonoids, Passiflora incarnata, standardization}, doi = {10.5530/pj.2019.11.178}, author = {Guseinov MD and Bobkova NV and Svistunov AA and Tarasov VV and Bokov DO and Sergunova EV and Kovaleva TYu} }